Stockreport

NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019

NANTKWEST  (NK) 
Last nantkwest earnings: 3/25 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.nantkwest.com
PDF Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety [Read more]